Abcam PLC has completed its acquisition of the proteomics and immunology businesses of Expedeon AG.

Abcam CEO Alan Hirzel said acquiring the German biotechnology company adds its product and technology portfolio to Abcam's antibody research and tools.

In November, Cambridge, England-based Abcam announced its intent to acquire Expedeon's three proteomics and immunology businesses — Expedeon Ltd., Innova Biosciences Ltd. and TGR BioSciences— for €120 million in cash.

In January 2019, Abcam bought antibodies developer Calico Biolabs Inc. to expand its production capabilities.